Now showing items 1-3 of 3

    • A new scenario in metastatic renal cell carcinoma: a SOG‑GU consensus 

      Vázquez Estévez, Sergio; Anido Herranz, Urbano; Lázaro Quintela, Martín; Fernández Calvo, Ovidio; Fernández-Núñez, Natalia; Dios Álvarez, N. de; Varela, V.; Campos Balea, B.; Agraso, S.; Areses, M. C.; Iglesias, L.; Blanco, Moisés; Maciá, S.; Antón-Aparicio, Luis M. (Springer, 2020-02-15)
      [Abstract] Background This article describes and compares approved targeted therapies and the newer immunotherapy agents. Materials and methods This article especially performs an in-depth review of currently available ...
    • Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor 

      Lázaro Quintela, Martín; León Mateos, Luis; Vázquez Estévez, Sergio; Fernández Calvo, Ovidio; Anido Herranz, Urbano; Afonso Afonso, Francisco Javier; Santomé, Lucía; Antón-Aparicio, Luis M. (Elsevier, 2015-03)
      [Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer ...
    • Radium-223 dichloride: a new paradigm in the treatment of prostate cancer 

      Anido Herranz, Urbano; Fernández Calvo, Ovidio; Afonso Afonso, Francisco Javier; Rodríguez Martínez de Llano, Sofía; Lázaro Quintela, Martín; León Mateos, Luis; Vázquez Estévez, Sergio; Antón-Aparicio, Luis M. (Taylor & Francis, 2015-01-02)
      [Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to ...